---
title: Reduce slowness stiffness and instability
nct_id: NCT06383247
phase: NA
status: RECRUITING
sponsor: Anhui Medical University
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06383247"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06383247"
last_fetched: "2026-05-10T14:01:41.016Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce slowness stiffness and instability

**Goal (in five words):** Reduce slowness stiffness and instability

**Official Title:** A Randomized, Double-blind, Multicenter, Placebo-controlled Trial (PRESS-PD)

**Trial ID:** [NCT06383247](https://clinicaltrials.gov/study/NCT06383247)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Anhui Medical University
- **Target Enrollment:** 290 participants
- **Start Date:** 2024-12-06
- **Completion Date:** 2026-12-31
- **Conditions:** Parkinson Disease, Transcranial Magenetic Stimualtion, Supplementary Motor Area
- **Interventions:** transcranial magnetic stimulation
- **Intervention Types:** OTHER

## Summary For Families

PRESS-PD is testing whether focused magnetic stimulation of the brain's supplementary motor area can ease core motor problems in Parkinson's, like slowness, stiffness, and unstable motor control. It uses repetitive transcranial magnetic stimulation, a noninvasive device that delivers magnetic pulses to change cortical excitability and strengthen motor circuit connections, and because it is not a drug it does not chemically interact with levodopa while participants keep stable medication doses. The trial is enrolling adults 40 and older with idiopathic Parkinson's, MDS-UPDRS part III score of at least 8, Hoehn‑Yahr stage 1 to 4, MMSE ≥22, stable meds for 4 weeks, and no epilepsy, metal implants, deep brain stimulation, major brain injury, or recent trial participation.

## Eligibility

- **Minimum age:** 40 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

1. Age ≥ 40 years old;
2. Meet the diagnostic criteria for idiopathic Parkinson's disease (MDS Diagnostic Criteria for Parkinson's Disease (2015 Edition))\[1\];
3. Have no history of drug adjustment within 4 weeks before treatment and the entire study period;
4. The MDS-UPDRS Ⅲ score ≥8, and the Hoehn-Yahr rating is 1-4;
5. MMSE ≥22，able to cooperate with the completion of behavioral tests and transcranial magnetic stimulation therapy.

Exclusion Criteria:

1. Previously head MRI/CT was focal brain injury or severe leukoencephalopathy (Fazekas grade 3 and above);
2. Various secondary parkinsonism syndromes (vascular parkinsonism, Parkinsonism combined with parkinsonism, drug parkinsonism, etc.);
3. Severe craniocerebral trauma, received craniocerebral surgery or deep brain stimulation treatment;
4. There are ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc.
5. The person has a history of epilepsy, unexplained loss of consciousness, or are taking anticonvulsant drugs to treat epileptic seizures;
6. Diagnosed with a neuropsychiatric disorder other than PD
7. Have a history of drug abuse or drug use;
8. Participants in any clinical trial within the previous 6 month;
9. Pregnant/lactating women or subjects (including men) who have a birth plan within 6 months;
10. Other conditions deemed unsuitable for inclusion by the investigator.
```

## Locations (1)

- Cognitive Neuropsychology Lab Anhui Medical University, Hefei, Anhui, China _(31.8639, 117.2808)_
  - panpan hu, M.D. — (CONTACT) — +8655162923704 — hpppanda9@126.com

## Central Contacts

- Panpan Hu, M.D. — (CONTACT) — +8613515602285 — hpppanda9@126.com
- Kai Wang, Ph.D. — (CONTACT) — +8655162923704 — wangkai1964@126.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT06383247*  
*HTML version: https://parkinsonspathways.com/trial/NCT06383247*  
*Source data: https://clinicaltrials.gov/study/NCT06383247*